A detailed history of Jane Street Group, LLC transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 59,541 shares of KZR stock, worth $446,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,541
Previous 549,062 89.16%
Holding current value
$446,557
Previous $329,000 86.32%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.53 - $0.77 $259,446 - $376,931
-489,521 Reduced 89.16%
59,541 $45,000
Q2 2024

Aug 14, 2024

BUY
$0.6 - $0.92 $314,695 - $482,533
524,493 Added 2134.78%
549,062 $329,000
Q1 2024

May 15, 2024

SELL
$0.8 - $1.05 $35,890 - $47,106
-44,863 Reduced 64.61%
24,569 $22,000
Q4 2023

Feb 14, 2024

BUY
$0.72 - $1.15 $49,991 - $79,846
69,432 New
69,432 $65,000
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.06 $178,583 - $236,565
77,309 Added 83.49%
169,906 $416,000
Q1 2023

May 15, 2023

BUY
$3.13 - $7.31 $241,864 - $564,865
77,273 Added 504.26%
92,597 $289,000
Q4 2022

Feb 14, 2023

SELL
$6.39 - $8.8 $62,462 - $86,020
-9,775 Reduced 38.95%
15,324 $107,000
Q3 2022

Nov 14, 2022

SELL
$7.99 - $10.75 $567,809 - $763,948
-71,065 Reduced 73.9%
25,099 $216,000
Q3 2022

Nov 14, 2022

SELL
$7.99 - $10.75 $567,809 - $763,948
-71,065 Reduced 73.9%
25,099 $216,000
Q2 2022

Aug 16, 2022

BUY
$4.58 - $17.13 $30,850 - $115,387
6,736 Added 7.53%
96,164 $795,000
Q1 2022

May 17, 2022

BUY
$12.3 - $18.33 $716,130 - $1.07 Million
58,222 Added 186.57%
89,428 $1.49 Million
Q4 2021

Feb 15, 2022

BUY
$7.44 - $16.72 $232,172 - $521,764
31,206 New
31,206 $522,000
Q3 2020

Nov 17, 2020

SELL
$4.36 - $5.5 $99,312 - $125,279
-22,778 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$3.6 - $7.75 $82,000 - $176,529
22,778 New
22,778 $118,000

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $513M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.